Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists

Joint Bone Spine. 2009 Jul;76(4):421-3. doi: 10.1016/j.jbspin.2008.12.004. Epub 2009 May 19.

Abstract

A 72-year-old male with a 4-year history of TNFalpha antagonist therapy (infliximab and etanercept) for ankylosing spondylitis was diagnosed with breast cancer. He had a family history of breast cancer. The low incidence and considerable severity of breast cancer in males, genetic risk factors, and potential role for TNFalpha antagonist therapy are discussed.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Breast Neoplasms, Male / diagnosis*
  • Breast Neoplasms, Male / genetics
  • Breast Neoplasms, Male / physiopathology
  • Etanercept
  • Genes, BRCA2
  • Genetic Predisposition to Disease
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Male
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Risk Factors
  • Spondylitis, Ankylosing / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept